Antihypertensive Effect of Different Doses of Rostafuroxin in Comparison With Losartan

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 240 participants.

Also called NCT03217825

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 240 participants (enrolled count) (from the registry)
Sponsor
Windtree Therapeutics (from the registry)
Registry
  • NCT NCT03217825
Other papers using this trial's data
  • Antihypertensive treatment guided by genetics: PEARL-HT, the randomized proof-of-concept trial comparing rostafuroxin with losartan The pharmacogenomics journal, 2021-06 DOI, PubMed 33649520, PMC8159753 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Taiwan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03217825. Randomized; triple masking; primary purpose treatment. Start 2015-12 (actual); primary completion 2018-02-08 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Antihypertensive Effect of Different Doses of Rostafuroxin in Comparison With Losartan
Condition
Hypertension
Intervention (Drug)
Rostafuroxin
Intervention (Drug)
Losartan
Lead sponsor
Windtree Therapeutics (class: industry)

Record details

Record id
cardio:ct-nct03217825
Content hash
48fa2797242536220b5cf88f43c9b780b29c715979e5b1fd18c79f7fc7e50552